Common Metabolic Enzyme Variants in Asian Populations
*Asian populations have distinctly higher frequencies of CYP2C19 loss-of-function alleles (particularly 2 and 3) and CYP2D610, while having lower frequencies of CYP2D64 and CYP2C1917 compared to Europeans, making them more likely to be poor metabolizers of drugs like clopidogrel and requiring different dosing strategies.**
Key Enzyme Variants by Frequency
CYP2C19 (Most Clinically Significant)
- CYP2C19*2: Most prevalent in South Asians (32.5%) and East Asians (31%), compared to only 15% in Europeans 1
- CYP2C19*3: Rare in Europeans (0.025%) but significantly more common in East Asians, though specific frequency varies 1
- CYP2C19*17: Substantially lower frequency in Singaporeans/Malaysians compared to Europeans 2
Clinical Impact: These loss-of-function variants result in 32% reduction in active metabolite levels for drugs like clopidogrel 1, leading to treatment failure in cardiovascular disease and requiring alternative antiplatelet agents.
CYP2D6 Variants
- CYP2D6*10: More common in Malays and Chinese populations 2
- CYP2D6*4: More prevalent in Europeans; among Asians, Indians show similar frequencies to Europeans while other Asian subgroups have lower frequencies 2
CYP3A4/5 Variants
- CYP3A4*1B (A-290G promoter substitution): Completely absent in Chinese, Malay, and Indian populations, but present in >54% of Africans and 5% of Caucasians 3
- CYP3A5: Frequency differences exist but require further study in Malaysian/Singaporean populations 2
Phase II Enzyme Variants
TPMT (Thiopurine Methyltransferase)
- TPMT*3C: The major mutant allele in Chinese populations at 2-3.2% frequency 4
- TPMT*3A: Most common in Caucasians (~5%) but less frequent in Asians 4
Dosing Algorithm for Azathioprine/Mercaptopurine 4:
- Two functional alleles: Start normal dose (2-3 mg/kg/day)
- One nonfunctional allele: Start 30-70% of target dose
- Two nonfunctional alleles: Reduce dose 10-fold or use alternative agent
ITPA (Inosine Triphosphate Pyrophosphatase)
- Loss-of-function variants (94C>A, IVS2+21A>C): Frequency of 11-15% in Asian populations versus 6% in Caucasians 4
GST and NAT2
- GSTM1*0 null genotype: 61-63% in Chinese and Malays versus only 33% in Indians 3
- NAT2: Requires further characterization in Malaysian/Singaporean populations 2
UGT1A1
- UGT1A1*28: Highest in Indians (35%), lower in Chinese (16%) and Malays (19%) 3
Transporter Variants
MDR1 (ABCB1)
- Exon 12 wild-type C allele: 34.2% in Malays, 32.8% in Indians, similar to Japanese (38.5%) and Caucasians (41%), but different from African-Americans (15%) 3
- TT genotype: Much higher in Asians (43.5-52.1%) and Japanese (61.5%) than Caucasians (13.3%) 3
Critical Clinical Considerations
HLA Variants (Not Metabolic Enzymes but Crucial)
HLA-B*15:02: Dramatically more common in Asians, conferring a 172-fold increased risk of Stevens-Johnson syndrome and toxic epidermal necrolysis with carbamazepine 5. This warrants mandatory screening before prescribing carbamazepine, phenytoin, or allopurinol in Asian patients.
Inter-Asian Homogeneity
Important caveat: Korean, Japanese, and Chinese populations show remarkable similarity in drug-metabolizing enzyme genetics, with fixation index <0.034 and correlation coefficient >0.95 for minor allele frequencies 6. This means dosing recommendations can often be extrapolated across East Asian subgroups, though South Asians (Indians, Pakistanis) show more divergence 2, 3.
Practical Implications
The most actionable variants for clinical practice are:
- *CYP2C192 and 3* for clopidogrel, PPIs, SSRIs
- HLA-B*15:02 for carbamazepine and related drugs
- TPMT variants for thiopurine dosing
- CYP2D6*10 for codeine, tamoxifen, and antidepressants
These variants occur at sufficiently high frequencies in Asian populations to justify preemptive genotyping for high-risk medications rather than reactive testing after adverse events 5.